BBIO vs HAL · rev $221.9M vs P/E 9.3, $19.05B cap
BridgeBio Pharma Inc (BBIO) versus Halliburton Company (HAL) — a side-by-side from cached financials, not a winner call.
BridgeBio Pharma Inc (BBIO) is a biotechnology company listed on US.
Halliburton Company (HAL) is a oil & gas equipment & services company listed on US.
Latest reported BBIO revenue for 2024-12-31 was $221.9M. Net income was -$543.3M. Revenue was up 2285.3% from 2023-12-31 to 2024-12-31. BBIO currently screens at market cap $13.24B.
HAL does not have a complete income-statement cache yet.
BBIO currently screens at market cap $13.24B. HAL currently screens at market cap $19.05B and trailing P/E 9.3.
Not investment advice. Open the BBIO and HAL stock pages for the full models.
Not investment advice.